Melinta Therapeutics, Inc.
http://www.melinta.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Melinta Therapeutics, Inc.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.
Marching On: Eight Novel Agents Among March Goal Dates For US FDA
Crowded calendar could bring to an end the slow start for novel approvals in 2024, as decisions come due for Lilly’s donanemab, Merck’s sotatercept, Regeneron’s odronextamab and more.
Deal Watch: Graphite Exits Via Reverse Merger With Presbyopia Specialist LENZ
Plus deals involving Abliva/Owl, Selecta/Cartesian, Novo Nordisk/Genevant, AbbVie/Aldeyra and more.
J&J Saves Cidara’s Flu ‘Drug Cocktail’ From Pipeline Purge
Cidara Therapeutics has been given a lifeline after Johnson & Johnson’s opt-in on its universal flu prevention treatment – though the big pharma is expected to pass it onto a third party.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Rib-X Pharmaceuticals, Inc.
- Cempra, Inc. (Cempra Pharmaceuticals, Inc.)
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice